Pteryxin

Pteryxin ((+) -Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a BChE inhibitor (IC50=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca2+-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease[1][2][3][4][5].

Product Specifications

CAS Number

[13161-75-6]

Product Name Alternative

(+) -Pteryxin

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cholinesterase (ChE) ; Keap1-Nrf2; NF-κB; NOD-like Receptor (NLR) ; Nuclear Factor of activated T Cells (NFAT) ; p38 MAPK; Reactive Oxygen Species (ROS)

Type

Natural Products

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pteryxin.html

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C=C(C)\C(O[C@@H]1C2=C3C(C=CC(O3)=O)=CC=C2OC(C)(C)[C@@H]1OC(C)=O)=O

Molecular Formula

C21H22O7

Molecular Weight

386.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhen D, et al. Pteryxin attenuates LPS-induced inflammatory responses and inhibits NLRP3 inflammasome activation in RAW264.7 cells. J Ethnopharmacol. 2022 Feb 10;284:114753.|[2]Sun R, et al. Pteryxin suppresses osteoclastogenesis and prevents bone loss via inhibiting the MAPK/Ca2+ signaling pathways mediated by ROS. Biomed Pharmacother. 2023 Sep;165:114898.|[3]Taira J, et al. Cytoprotective Effect of Pteryxin on Insulinoma MIN6 Cells Due to Antioxidant Enzymes Expression via Nrf2/ARE Activation. Antioxidants (Basel) . 2023 Mar 10;12 (3) :693.|[4]Kiris I, et al. Molecular Effects of Pteryxin and Scopoletin in the 5xFAD Alzheimer's Disease Mouse Model. Curr Med Chem. 2022;29 (16) :2937-2950.|[5]Orhan IE, et al. Pteryxin - A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea. Food Chem Toxicol. 2017 Nov;109 (Pt 2) :970-974.